Continuous care in radiotherapeutic oncology: Control of chronic symptoms. Secondary effects of treatments with radiotherapy and chemotherapy;Control de sińtomas crónicos. Efectos secundarios del tratamiento con radioterapia y quimioterapia

Oncologia

Volumn 28, Issue 3, 2005, Pages 41-50

  Montero, A ^a   Hervas A ^a   Morera, R ^a   Sancho, S ^a   Cordoba S ^a   Corona, J A ^a   Rodriguez I ^a   Chajon E ^a   Ramos, A ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; ALPHA TOCOPHEROL; AMIFOSTINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; COPPER ZINC SUPEROXIDE DISMUTASE; CORTICOSTEROID; CYTARABINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUDARABINE; FLUOROURACIL; HYALURONIC ACID; INTERLEUKIN 1; INTERLEUKIN 6; MANGANESE SUPEROXIDE DISMUTASE; METHOTREXATE; OXALIPLATIN; PENTOXIFYLLINE; PILOCARPINE; PODOPHYLLOTOXIN; SILDENAFIL; SUCRALFATE; TAXANE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VINCA ALKALOID;

BONE NECROSIS; BRAIN DISEASE; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARDIOMYOPATHY; CENTRAL NERVOUS SYSTEM DISEASE; COGNITIVE DEFECT; CONFERENCE PAPER; CORONARY ARTERY DISEASE; ENTEROPATHY; ERECTILE DYSFUNCTION; ESOPHAGITIS; FIBROSIS; HEARING IMPAIRMENT; HEART MUSCLE CONDUCTION DISTURBANCE; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HYPERBARIC OXYGEN; HYPOTHYROIDISM; INFLAMMATION; IONIZING RADIATION; LEUKOENCEPHALOPATHY; LIVER TOXICITY; LYMPHEDEMA; MYELITIS; PATHOPHYSIOLOGY; PERICARDITIS; PERIPHERAL NEUROPATHY; PNEUMONIA; RADIATION DOSE; RADIATION INJURY; RADIATION NECROSIS; RECTUM DISEASE; REPRODUCTIVE TOXICITY; TOOTH DISEASE; VAGINA DISEASE; XEROSTOMIA;

EID: 19144366751     PISSN: 03784835     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (85)

1. Bentzen SM, Darr W, Anscher MS, et al. Normal tissue effects: Reporting and analysis. Semin Radiat Oncol. 2003;13(3):189-202.
2. Delanian S, Martin M, Housset M. Iatrogenic fibrosis in cancerology (1): descriptive and physiapathological aspects. Bull Cancer. 1993;80(3):192-201.
3. Cax JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341-6.
4. Rubin P, Constine LS, Fajardo LF, Phillips TL, Wasserman TH. RTOG Late Effects Working Group. Overview. Late Effects of Normal Tissues(LENT) scoring system. Int J Radiat Oncol Biol Phys. 1995;31(5):1041-2.
5. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0. on improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47(1):13-47.
6. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176-81.
7. Rubin P, Casarett GW. Clinical radiation pathology as applied to curative radiotherapy. Cancer. 1968 Oct;22(4):767-78.
8. Williams J, Chen Y, Rubin P, Finkelstein J, Okunieff P. The biological basis of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):182-8.
9. Colemon CN, Harris JR. Current scientific issues related to clinical radiation oncology. Radiat Res. 1998 Aug;150(2):125-33.
10. Fedyk ER, Jones D, Critchley HO, et al. Expression of stromol-derived factor-1 is decreased by IL-1 and TNF and in dermal wound healing. J Immunol. 2001;166(9):5749-54.
11. Mercada AM, Padgett DA, Sheridan JF, Marucha PT. Altered kinetics of IL-1 alpha, IL-1 beta, and KGF-1 gene expression in early wounds of restrained mice. Brain Behav Immun. 2002;16(2):150-62.
12. Petak I, Houghton JA. Shared pathways: death receptors and cytotoxic drugs in cancer therapy. Pathol Oncol Res. 2001;7(2):95-106.
13. Zheng H, Wong J, Koteliansky VE, Gotwals PJ, Hauer-Jensen M. Recombinant soluble transforming growth factor beta type II receptor ameliorates radiation enteropathy in mice. Gastroenterology. 2000;119(5):1286-96.
14. Wang JF, Olson ME, Reno CR, Kulyk W, Wright JB, Hart DA. Molecular and cell biology of skin wound healing in a pig model. Connect Tissue Res. 2000;41(3):195-211.
15. Meadows AT, Silber J. Delayed consequences of therapy for childhood cancer. CA Cancer J Clin. 1985;35(5):271-86.
16. Meadows AT, Baum E, Fossoti-Bellani F, et al. Second malignant neoplasms in children: an update from the Late Effects Study Group. J Clin Oncol. 1985;3(4):532-8.
17. Ewing J. Radiation osteitis. Acta Radiol 1926;6:399-412.
18. Andrews N, Griffiths C. Dental complications of head and neck radiotherapy: Part 1. Aust Dent J. 2001;46(2):88-94.
19. Andrews N, Griffiths C. Dental complications of head and neck radiotherapy: Part 2. Aust Dent J. 2001;46(3):174-82.
20. Kumar AJ, Leeds NE, Fuller GN, Van Tassel P, et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology. 2000;217(2):377-84
21. Sheline GE. The rale of radiation therapy in the treatment of low-grade gliomas. Clin Neurosurg. 1986;33:563-74.
22. Delattre JY, Rosenblum MK, Thaler HT, et al. A model of radiation myelopathy in the rat. Pathology, regional capillary permeability changes and treatment with dexamethasone. Brain. 1988;111(Pt 6):1319-36.
23. Davidsan A, Tait DM, Payne GS, et al. Magnetic resonance spectroscopy in the evaluation of neurotoxicity fallowing cranial irradiation for childhood cancer. Br J Radiol. 2000;73(868):421-4.
24. Langleben DD, Segall GM. PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med. 2000;41(11):1861-7.
25. Silber JH, Radcliffe J, Peckham V, et al. Whole-brain irradiation and decline in intelligence: the influence of dose and age on IQ score. J Clin Oncol. 1992;10(9):1390-6.
26. Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med. 1993 17;328(24):1725-31.
27. Keime-Guibert F, Napolitano M, Delattre JY. Neurological complications of radiotherapy and chemotherapy. J Neurol. 1998;245(11):695-708.
28. Gonzalez H, Bolgert F, Camporo P, Leblond V. Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP). Hematol Cell Ther. 1999 Aug;41(4):183-6.
29. Herzig RH, Hines JD, Herzig GP, Wolff SN, et al. Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol. 1987;5(6):927-32.
30. Tuchman M, Staeckeler JS, Kiang DT, et al. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med. 1985;313(4):245-9.
31. Blay JY, Conroy T, Chevreau C, et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol. 1998;16(3):864-71.
32. Rampling R, Symonds P. Radiation myelopathy. Curr Opin Neurol. 1998;11(6):627-32.
33. McCunniff AJ, Liang MJ. Radiation tolerance of the cervical spinal cord. Int J Radiat Oncol Biol Phys. 1989;16(3):675-8.
34. St. Clair WH, Arnold SM, Sloan AE, Regine WF. Spinal cord and peripheral nerve injury: current management and investigations. Semin Radiat Oncol 2003;13:322-332.
35. Mossman K, Shatzman A, Chencharick J. Long-term effects of radiotherapy on taste and salivary function in man. Int J Radiat Oncol Biol Phys. 1982;8(6):991-7.
36. Eneroth CM, Henrikson CO, Jakobsson PA. Effect of fractionated radiotherapy on salivary gland function. Cancer. 1972;30(5):1147-53.
37. Berthrong M, Fajardo LF. Radiation injury in surgical pathology. Part II. Alimentary tract. Am J Surg Pathol. 1981;5(2):153-78.
38. Marks LB, Yu X, Vujaskovic Z, Small W Jr, Folz R, Anscher MS. Radiation-induced lung injury. Semin Radiat Oncol. 2003;13(3):333-45
39. Marks LB. The pulmonary effects of thoracic irradiation. Oncology (Huntingt). 1994;8(6):89-106.
40. Garipagaoglu M, Munley MT, Hallis D, et al. The effect of patient-specific factors an radiation-induced regional lung injury. Int J Radiat Oncol Biol Phys. 1999;45(2):331-8.
41. Dechambre S, Dorzee J, Fastrez J, et al. Bronchial stenosis and sclerosing mediastinitis: an uncommon complication of external thoracic radiotherapy. Eur Respir J. 1998;11(5):1188-90.
42. Rutqvist LE, Rose C, Cavallin-Stahl E. A systematic overview of radiation therapy effects in breast cancer. Acta Oncol. 2003;42(5-6):532-45.
43. Carmel RJ, Kaplan HS. Mantle irradiation in Hodgkin's disease. An analysis of technique, tumor eradication, and complications. Cancer. 1976;37(6):2813-25.
44. Carlson RG, Mayfield WR, Normann S, Alexander JA. Radiation-associated valvular disease. Chest. 1991;99(3):538-45.
45. Orzan F, Brusca A, Conte MR, Presbitero P, Figliomeni MC. Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment. Br Heart J. 1993;69(6):496-500.
46. Slama MS, Le Guludec D, Sebag C, et al. Complete atrioventricular block following mediastinal irradiation: a report of six cases. Pacing Clin Electrophysiol. 1991;14(7):1112-8.
47. Warda M, Khan A, Massumi A, Mathur V, Klima T, Hall RJ. Radiation-induced valvular dysfunction. J Am Coll Cardiol. 1983;2(1):180-5.
48. Van Renterghem D, Hamers J, De Schryver A, Pauwels R, Van der Straeten M. Chylothorax after mantle field irradiation for Hodgkin's disease. Respiration. 1985;48(2):188-9.
49. Yeoh E, Horowitz M, Russo A, et al. A retrospective study of the effects of pelvic irradiation for carcinoma of the cervix on gastrointestinal function. Int J Radiat Oncol Biol Phys. 1993;26(2):229-37.
50. Husebye E, Hauer-Jensen M, Kjorstad K, Skar V. Severe late radiation enteropathy is characterized by impaired motility of proximol small intestine. Dig Dis Sci. 1994;39(11):2341-9.
51. Pearse HD. The urinary bladder. En: Moss' Radiation Oncology 7th edition. JD Cox, editor, pp 518-555. Mosby, 1994 S. Luis, EE.UU.
52. Roach M, Winter K, Michalski JM, et al. Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study. Int J Radiat Oncol Biol Phys. 2004;60(5):1351-6.
53. Wernicke AG, Valicenti R, Dieva K, Houser C, Pequignot E. Radiation dose delivered to the proximal penis as a predictor of the risk of erectile dysfunction after three-dimensional conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004;60(5):1357-63.
54. McLaughlin PW, Narayana V, Meriowitz A, et al. Vessel-sparing prostate radiotherapy: dose limitation to critical erectile vascular structures (internal pudendal artery and corpus cavernosum) defined by MRI. Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):20-31.
55. Delanian S, Baillet F, Huart J, et al. Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase: clinical trial. Radiother Oncol. 1994;32(1):12-20.
56. Valencia J, Velilla C, Urpegui A, et al. Bascan N, Esco R. The efficacy of orgotein in the treatment of acute toxicity due to radiotherapy on head and neck tumors. Tumori. 2002 Sep-Oct;88(5):385-9.
57. Lefaix JL, Delanian S, Leplat JJ, et al. [Radiation-induced cutaneo-muscular fibrosis (III): major therapeutic efficacy of liposomal Cu/Zn superoxide dismutase] Bull Cancer. 1993 Sep;80(9):799-807.
58. Delanian S, Martin M, Housset M. [Iatrogenic fibrosis in cancerology (1): descriptive and physiopathological aspects] Bull Cancer. 1993 Mar;80(3):192-201.
59. Delanian S, Lefaix JL, Housset M. [Iatrogenic fibrosis in cancerology (2): main etiologies and therapeutic possibilities] Bull Cancer. 1993 Mar;80(3):202-12.
60. Ruiz Martín V, Algara López M, Foro Arnalot A, et al. Eficacia de la orgoteina en el tratamiento de la fibrosis y xerostomía radioinducidas. Oncología 1995; 18:60-64.
61. O'Sullivan B, Levin W. Late radiation-related fibrosis: pathogenesis, manifestations, and current management. Semin Radiat Oncol. 2003;13(3):274-89.
62. Duncan MR, Hoson A, Bermon B. Pentoxifylline, pentifylline, and interferons decrease type I and III procollagen mRNA levels in dermal fibroblasts: evidence for mediation by nuclear factor 1 down-regulation. J Invest Dermatol. 1995;104(2): 282-6.
63. Berman B, Wietzerbin J, Sonceau J, et al. Pentoxifylline inhibits certain constitutive and tumor necrosis factor-alpha-induced activities of human normal dermal fibroblasts. J Invest Dermatol. 1992;98(5):706-12.
64. Futran ND, Trotti A, Gwede C. Pentoxifylline in the treatment of radiation-related soft tissue injury: preliminary observations. Laryngoscope. 1997;107(3):391-5.
65. Steeves RA, Robins HI. Pentoxifylline treatment of radiation mostitis. Int J Radiat Oncol Biol Phys. 1998;42(5):1177.
66. Delonion S, Bollo-Mekias S, Lefaix JL. Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol. J Clin Oncol. 1999;17(10):3283-90.
67. Evans ML, Grohom MM, Mahler PA, Rosey JS. Use of steroids to suppress vascular response to radiation. Int J Radiat Oncol Biol Phys. 1987;13(4):563-7.
68. Geraci JP, Mariano MS, Jackson KL. Amelioration of radiation nephropathy in rats by dexamethasone treatment after irradiation. Radiat Res. 1993;134(1):86-93.
69. Roberts NA, Robinson PA. Copper chelates of antirheumatic and anti-inflammatory agents: their superoxide dismutase-like activity and stability. Br J Rheumatol. 1985;24(2):128-36.
70. Word WF, Molteni A, Ts'ao CH, et al. Radiation pneumotoxicity in rats: modification by inhibitors of angiotensin converting enzyme. Int J Radiat Oncol Biol Phys. 1992;22(3):623-5.
71. Ward WF, Molteni A, Ts'oo CH, Hinz JM. Captopril reduces collagen and mast cell accumulation in irradiated rat lung. Int J Radiat Oncol Biol Phys. 1990;19(6):1405-9.
72. Word WF, Kim YT, Molteni A, Solliday NH. Radiation-induced pulmonary endothelial dysfunction in rats: modification by an inhibitor of angiotensin converting enzyme. Int J Radiat Oncol Biol Phys. 1988;15(1):135-40.
73. Molteni A, Moulder JE, Cohen EP, et al. Prevention of radiation-induced nephropathy and fibrosis in a model of bone marrow transplant by an angiotensin II receptor blacker. Exp Biol Med 2001;226(11):1016-23.
74. Kochhar R, Patel F, Dhar A, et al. Radiation-induced proctosigmoiditis. Prospective, randomized, double-blind controlled trial of oral sulfasalozine plus rectal steroids versus rectal sucralfate. Dig Dis Sci. 1991;36(1):103-7.
75. Liguori V, Guillemin C, Pesce GF, et al. Double-blind, randomized clinical study comparing hyoluronic acid cream to placebo in patients treated with radiotherapy Radiother Oncol. 1997;42:155-61.
76. Wassermon T. Radioprotective effects of omifastine. Semin Oncol. 1999;26(2 Suppl 7):89-94.
77. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of omifastine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18(19):3339-45.
78. Antonadau D, Coliarakis N, Synodinou M, et al. Randomized phase III trial of radiation treatment +/- omifastine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys. 2001;51(4):915-22.
79. Ben-Josef E, Hon S, Tobi M, Vargas BJ, et al. Intrarectal application of amifastine for the prevention of radiation-induced rectal injury. Semin Radiat Oncol. 2002;12(1 Suppl 1):81-5.
80. Johnson JT, Ferretti GA, Nethery WJ, Valdez IH, et al. Oral pilocorpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med. 1993;329(6):390-5.
81. LeVeque FG, Montgomery M, Potter D, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-titrotion study of oral pilocarpine for treatment of radiation-induced xerostamia in head and neck cancer patients. J Clin Oncol. 1993;11(6):1124-31.
82. Zelefsky MJ, McKee AB, Lee H, Leibel SA. Efficacy of oral sildenafil in patients with erectile dysfunction after radiotherapy for carcinoma of the prostate. Urology. 1999;53(4):775-8.
83. Feldmeier JJ. Hyperbaric oxygen for delayed radiation injuries. Undersea Hyperb Med. 2004;31(1):133-45.
84. Feldmeier JJ, Hampson NB. A systematic review of the literature reporting the application of hyperbaric oxygen prevention and treatment of delayed radiation injuries: an evidence based approach. Undersea Hyperb Med. 2002;29(1):4-30.
85. Mayer R, Klemen H, Quehenberger F, et al. Hyperbaric oxygen - an effective tool to treat radiation morbidity in prostate cancer. Radiother Oncol. 2001;61(2):151-6.